# EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection

> **NCT00105183** · PHASE3 · COMPLETED · sponsor: **Neovii Biotech** · enrollment: 223 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary
- Idiopathic Pulmonary Fibrosis
- Cystic Fibrosis
- Bronchiectasis
- Pulmonary Vascular Disease

## Interventions

- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** EZ-2053
- **BIOLOGICAL:** EZ-2053 5mg/kg

## Key facts

- **NCT ID:** NCT00105183
- **Lead sponsor:** Neovii Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2010-01
- **Final completion:** 2011-01
- **Target enrollment:** 223 (ACTUAL)
- **Last updated:** 2012-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00105183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00105183, "EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00105183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*